Connect with LRI:
Facebook
Twitter
YouTube
Change.org

Lupus Clinical Trials

New Medical Therapies™

Platelet Disorders

Patient Medical Areas

December 12, 2005

GlaxoSmithKline and Ligand have reported positive results of a phase II trial of their investigational small molecule thrombopoietic eltrombopag (SB-497115), for the treatment of idiopathic thrombocytopenia purpura (ITP). Results indicated that the two highest doses of the drug significantly increased the portion of patients with platelet counts above 50,000 at 6 weeks, compare to placebo (66% for 50 mg/day, 87% for 75 mg/day, vs. 13% for placebo; p=<0.001). Results were not significant for the lowest trial dose (p=0.98). Incidence of overall adverse events was comparable between drug and placebo cohorts, and serious adverse events occurred in a lower portion of subjects receiving eltrombopag (7.7%) than placebo (15%). This randomized, double-blind, placebo-controlled dose-ranging study enrolled 95 adult patients with chronic refractory ITP, who received daily administration of one of 3 doses of the drug (30 mg, 50 mg or 75 mg) or placebo for 6 weeks.

August 29, 2005

Baxter Healthcare reported positive results from a multi trials investigating Advate, a recombinant antihemophilic factor for the treatment of hemophilia A. The first results were from a preliminary assessment of a prospective international, multi-center study enrolling 53 pediatric subjects less than six years of age who were previously treated with factor VIII. Results demonstrated that no patients discontinued therapy as a result of an adverse event and no incidence of factor VIII antibodies were reported in this study. The second were of preliminary results of a multi- center, prospective, open-label, uncontrolled study designed to test the efficacy, safety and immunogenicity on 57 hemophilia A subjects undergoing surgery or other invasive procedures. An interim assessment of the first 44 procedures performed demonstrated an efficacy rating of excellent/good in 97.7% of surgeries. The company presented the data at the 20th Congress of the International Society on Thrombosis and Haemostasis held in Sydney, Australia.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.